A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Recruiting

Phase 2

ForalumabA Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor:

Tiziana Life Sciences LTD

Code:

NCT06292923

Conditions

Secondary Progressive Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Foralumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-24. This information was provided to ClinicalTrials.gov by Tiziana Life Sciences LTD on 2025-10-15.